Disclosures. Dee Shortridge, PhD, AbbVie (formerly Allergan) (Research Grant or Support); Melinta Therapeutics, Inc. (Research Grant or Support); Melinta Therapeutics, LLC (Research Grant or Support); Shionogi (Research Grant or Support); Spero Therapeutics, Inc. (Research Grant or Support); Jennifer M. Streit, BS, GlaxoSmithKline, LLC (Research Grant or Support); Melinta Therapeutics, LLC (Research Grant or Support); Shionogi (Research Grant or Support); Spero Therapeutics (Research Grant or Support); Michael D. Huband, BS, AbbVie (formerly Allergan) (Research Grant or Support); Melinta Therapeutics, LLC (Research Grant or Support); Mariana Castanheira, PhD, AbbVie (formerly Allergan) (Research Grant or Support); Bravo Biosciences (Research Grant or Support); Cidara Therapeutics, Inc. (Research Grant or Support); Cipla Therapeutics (Research Grant or Support); Cipla USA Inc. (Research Grant or Support); GlaxoSmithKline (Research Grant or Support); Melinta Therapeutics, Inc. (Research Grant or Support); Pfizer, Inc. (Research Grant or Support); Qpex Biopharma (Research Grant or Support); Shionogi (Research Grant or Support); Spero Therapeutics (Research Grant or Support); Mariana Castanheira, PhD, Affinity Biosensors (Individual(s) Involved: Self); Research Grant or Support; Amicrobe, Inc. (Individual(s) Involved: Self); Research Grant or Support; Ampyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beastlifer (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contraxel (Individual(s) Involved: Self): Research Grant or Support; Cordexa (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; CuraTherapeutics (Individual(s) Involved: Self): Research Grant or Support; CXCL7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; ForaChase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardant Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; HIDMA (Individual(s) Involved: Self): Research Grant or Support; Hisonix (Individual(s) Involved: Self): Research Grant or Support; Jansen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosciences (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Laminox (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuruRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; National Institute of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEx Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RHI ML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; SalvaC (Individual(s) Involved: Self): Research Grant or Support; Scy nexis (Individual(s) Involved: Self): Research Grant or Support; Sclux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Health Science Center at Houston (Individual(s) Involved: Self): Research Grant or Support; University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support;
Table 1. Oral Antimicrobial Test Prescription Result (n=75)

| ETP result                                    | N (%) |
|----------------------------------------------|-------|
| Approved without an out of pocket cost       | 16 (21)|
| Approved with an out of pocket cost          | 33 (44)|
| Cost (median [IQR])                          | $14 ($4 - $55) |
| Denied                                       | 14 (19)|
| Denied, PA required                          | 8 (11)|
| Denied, other reason                         | 6 (8)|
| Other barriers                               | 12 (16)|

**Conclusion.** A standardized eTP process appears to be a safe way to evaluate out of pocket cost without prolonging length of stay. Future work will focus on inequity in access to first line ABX.

**Disclosures.** No reported disclosures

---

158. Impact of Fluoroquinolone Cascade Reporting of Urine Samples on Antibiotic Prescribing Rates in a Network of Urgent Care Clinics

Britanni Weichman, PharmD Student; Amanda Bushman, PharmD; Rossana M. Rosa, MD; UnityPoint Des Moines Iowa Lutheran Hospital, Des Moines, IA; UnityPoint Health, Des Moines, IA

**Session:** O-32. Stewardship in Ambulatory Settings

**Background.** Cost barriers to accessing discharge oral antimicrobials (ABX) may delay discharges and result in suboptimal discharge ABX. Use of electronic test prescriptions (eTP) or “price checks” is controversial due to potential for erroneous dispensing. This study evaluated discharge ABX access and outcome after implementation of a standardized, inpatient pharmacist-initiated ABX eTP process in collaboration with discharge pharmacy.

**Methods.** IRB approved, retrospective, cross-sectional cohort pilot-study. Inclusion: home bound adults admitted for ≥72 hours from 1/1/18-2/28/19 and discharged on oral ABX. Patients with an ABX eTP prior to discharge were compared to those discharged on ABX but no eTP. Data were reported using descriptive statistics and bivariate analysis. Primary endpoint: discharge delay after medical stability. Secondary endpoints: medication access, unplanned encounters, and % of patients discharged on first-line ABX.

**Results.** 84 patients included: 43 no-ETP and 41 eTP. 75 ABX eTP evaluated among 41 patients. Patients in the no-ETP group had higher Charlson comorbidity index (P = 0.044) and immunosuppression (24% vs. 12%; P = 0.014). Median length of stay, days: 6 (5 – 9) eTP vs. 8 (5 – 15) no-eTP (P = 0.026). Most common eTP requested by pharmacist: linezolid (17, 23%) and oral vancomycin (12, 16%) (Figure 1). eTP results were documented in the medical record in < 24 hours for 66 (88%) of inquiries. 49 (65%) prescriptions were approved by insurance; 16 (21%) had no out of pocket cost and 8 (11%) required prior authorization (PA) (Table 1). Linezolid (5, 35%) and vancomycin (10, 71%) were frequently associated with barriers. 29 (70%) patients were discharged on the same ABX as the eTP. There were no discharge delays or erroneous dispensing. 14 (33%) no-eTP and 15 (37%) eTP patients experienced unplanned healthcare encounters after discharge. 9/84 (11%) patients were discharged on suboptimal ABX. Non-white race 8/9 (89%) PA = 0.047 and public insurance 8/9 (89%) P = 0.063 were associated with suboptimal discharge ABX.

**Conclusion.** A standardized eTP process appears to be a safe way to evaluate out of pocket cost without prolonging length of stay. Future work will focus on inequity in access to first line ABX.

**Disclosures.** Nothing to disclose Rachel Kenney, PharmD, Medtronic, Inc. (Other Financial or Material Support, spouse is an employee and shareholder)

---

157. Impact of Pharmacist-Generated Oral Antimicrobial Test Prescription on Discharge Medication Access and Outcome

Surafel Meluga, PharmD, MS, BCP®; Susan L. Davis, PharmD; Susan L. Davis, PharmD; Rachel Kenney, PharmD, Henry Ford Hospital, Detroit, MI; Wayne State University, Detroit, MI

**Session:** O-32. Stewardship in Ambulatory Settings

**Background.** Cascade reporting is a type of selective reporting in which susceptibility results of certain antibiotics (either with broader spectrum or cost) are only reported if an organism is resistant to other prespecified agents. This strategy has been successfully deployed in inpatient settings but its impact in outpatient settings is less well characterized. Therefore, we aimed to evaluate the impact of cascade reporting of the antimicrobial susceptibility of fluoroquinolones on prescribing rates of select antibiotics in a network of urban Urgent Care clinics.

**Methods.** On July 2019, the susceptibility reporting policies for urine cultures growing Enterobacterales were changed to routinely reporting a limited antibiotic panel including first and second generation cephalosporins, nitrofurantoin and